. 2020 Dec 22;44(3):337–349. doi: 10.1007/s40264-020-01021-3

Table 3.

Distribution of Individual Case Safety Reports having alirocumab or evolocumab as the suspected drugs, by therapeutic indication

Variable	Level	All ICSRs [n = 2041]	ICSRs reporting alirocumab as the suspect drug [n = 856]	ICSRs reporting evolocumab as the suspect drug [n = 1231]
Therapeutic indication	Lipid metabolism disorder	1423^b (69.7)	579^b (67.6)	870^b (70.7)
	Cardiovascular disorders	176^b (8.6)	55^b (6.4)	123^b (10)
	Product used for unknown indication	635^b (31.1)	271^b (31.6)	386^b (31.3)
	Other therapeutic indications^a	18^b (0.8)	7^b (0.8)	11^b (0.9)

Data are expressed as n (%)

ICSRs Individual Case Safety Reports

^aOther therapeutic indications: clinical trial participant; diabetes mellitus; disease risk factor; drug intolerance/drug hypersensitivity; hypolipidaemia; ill-defined disorder; intentional overdose; multiple sclerosis; plasmacytoma; product use in unapproved indication; routine health maintenance; dyspnea

^bThe sum of therapeutic indications reported in ICSRs is higher than the total number of ICSRs, since more than one therapeutic indication can be reported in each ICSR